Larotrectinib for the treatment of TRK fusion solid tumors

References

• Rubin JB. Segal RA: growth, survival and migration: the Trk to cancer. Cancer Treat Res. 2003;115:1–18.
   PubMedGoogle Scholar
• Nakagawara A. Trk receptor tyrosine kinases: a bridge between cancer and neural development. Cancer Lett. 2001;169:107–114.
   PubMed Web of Science ®Google Scholar
• Ivanisevic L, Saragovi HU. Chapter 224 - neurotrophins A2 - Kastin, Abba J, handbook of biologically active peptides (Second Edition). Boston: Academic Press; 2013. p. 1639–1646.
   Google Scholar
• Farinas I, Wilkinson GA, Backus C, et al. Characterization of neurotrophin and Trk receptor functions in developing sensory ganglia: direct NT-3 activation of TrkB neurons in vivo. Neuron. 1998;21:325–334.
   PubMed Web of Science ®Google Scholar
• Gupta VK, You Y, Gupta VB, et al. TrkB receptor signalling: implications in neurodegenerative, psychiatric and proliferative disorders. Int J Mol Sci. 2013;14:10122–10142.
   PubMed Web of Science ®Google Scholar
• Martin-Zanca D, Hughes SH. Barbacid M: a human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences. Nature. 1986;319:743–748.
   PubMed Web of Science ®Google Scholar
• Knezevich SR, McFadden DE, Tao W, et al. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet. 1998;18:184–187.
   PubMed Web of Science ®Google Scholar
• Knezevich SR, Garnett MJ, Pysher TJ, et al. ETV6-NTRK3 gene fusions and trisomy 11 establish a histogenetic link between mesoblastic nephroma and congenital fibrosarcoma. Cancer Res. 1998;58:5046–5048.
   PubMed Web of Science ®Google Scholar
• El Demellawy D, Cundiff CA, Nasr A, et al. Congenital mesoblastic nephroma: a study of 19 cases using immunohistochemistry and ETV6-NTRK3 fusion gene rearrangement. Pathology. 2016;48:47–50.
   PubMed Web of Science ®Google Scholar
• Tognon C, Knezevich SR, Huntsman D, et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell. 2002;2:367–376.
   PubMed Web of Science ®Google Scholar
• Skalova A, Vanecek T, Sima R, et al. Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity. Am J Surg Pathol. 2010;34:599–608.
   PubMed Web of Science ®Google Scholar
• Vaishnavi A, Capelletti M, Le AT, et al. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med. 2013;19:1469–1472.
   PubMed Web of Science ®Google Scholar
• Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in trk fusion-positive cancers in adults and children. N Engl J Med. 2018;378:731–739.
   PubMed Web of Science ®Google Scholar
• Creancier L, Vandenberghe I, Gomes B, et al. Chromosomal rearrangements involving the NTRK1 gene in colorectal carcinoma. Cancer Lett. 2015;365:107–111.
   PubMed Web of Science ®Google Scholar
• Wiesner T, He J, Yelensky R, et al. Kinase fusions are frequent in Spitz tumours and spitzoid melanomas. Nat Commun. 2014;5:3116.
   PubMed Web of Science ®Google Scholar
• Laetsch TW, DuBois SG, Mascarenhas L, et al. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study. Lancet Oncol. 2018;19:705–714.
   PubMed Web of Science ®Google Scholar
• Rudzinski ER, Lockwood CM, Stohr BA, et al. Pan-Trk immunohistochemistry identifies NTRK rearrangements in pediatric mesenchymal tumors. Am J Surg Pathol. 2018;42:927–935.
   PubMed Web of Science ®Google Scholar
• Pavlick D, Schrock AB, Malicki D, et al. Identification of NTRK fusions in pediatric mesenchymal tumors. Pediatr Blood Cancer. 2017;64.
   PubMed Web of Science ®Google Scholar
• Gatalica Z, Xiu J, Swensen J, et al. Molecular characterization of cancers with NTRK gene fusions. Mod Pathol. 2018.
   PubMedGoogle Scholar
• Wong V, Pavlick D, Brennan T, et al. Evaluation of a congenital infantile fibrosarcoma by comprehensive genomic profiling reveals an LMNA-NTRK1 gene fusion responsive to crizotinib. J Natl Cancer Inst. 2016;108.
   Google Scholar
• Davis JL, Lockwood CM, Albert CM, et al. Infantile NTRK-associated mesenchymal tumors. Pediatr Dev Pathol. 2017;21:68-78.
   PubMed Web of Science ®Google Scholar
• Church AJ, Calicchio ML, Nardi V, et al. Recurrent EML4-NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy. Mod Pathol. 2018;31:463-473.
   Web of Science ®Google Scholar
• van Grotel M, Blanco E, Sebire NJ, et al. Distant metastatic spread of molecularly proven infantile fibrosarcoma of the chest in a 2-month-old girl: case report and review of literature. J Pediatr Hematol Oncol. 2014;36:231–233.
   PubMed Web of Science ®Google Scholar
• Lagree M, Toutain F, Revillon Y, et al. [Recurrent and metastatic infantile fibrosarcoma: a case report]. Arch Pediatr. 2011;18:28–32.
   PubMed Web of Science ®Google Scholar
• Tannenbaum-Dvir S, Glade Bender JL, Church AJ, et al. Characterization of a novel fusion gene EML4-NTRK3 in a case of recurrent congenital fibrosarcoma. Cold Spring Harb Mol Case Stud. 2015;1:a000471.
   PubMed Web of Science ®Google Scholar
• Amatu A, Sartore-Bianchi A. Siena S: NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open. 2016;1:e000023.
   PubMed Web of Science ®Google Scholar
• Russell JP, Powell DJ, Cunnane M, et al. The TRK-T1 fusion protein induces neoplastic transformation of thyroid epithelium. Oncogene. 2000;19:5729–5735.
   PubMed Web of Science ®Google Scholar
• Wai DH, Knezevich SR, Lucas T, et al. The ETV6-NTRK3 gene fusion encodes a chimeric protein tyrosine kinase that transforms NIH3T3 cells. Oncogene. 2000;19:906–915.
   PubMed Web of Science ®Google Scholar
• Laetsch TW, Nagasubramanian R, Casanova M. Targeting NTRK fusions for the treatment of congenital mesoblastic nephroma. Pediatr Blood Cancer. 2018;65.
   Web of Science ®Google Scholar
• Bailey JJ, Schirrmacher R, Farrell K, et al. Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I. Expert Opin Ther Pat. 2017;27:733–751.
   PubMed Web of Science ®Google Scholar
• Bailey JJ, Schirrmacher R, Farrell K, et al. Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II. Expert Opin Ther Pat. 2017;27:831–849.
   PubMed Web of Science ®Google Scholar
• Drilon A, Siena S, Ou SI, et al. Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). Cancer Discov. 2017;7:400–409.
   PubMed Web of Science ®Google Scholar
• Taylor J, Marcelus C, Pavlick D, et al. Characterization of Ntrk fusions and therapeutic response to Ntrk inhibition in hematologic malignancies. Blood. 2017;130:794.
   Web of Science ®Google Scholar
• Hyman DM, Laetsch TW, Kummar S, et al. The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers. J Clin Oncol. 2017;35:LBA2501–LBA2501.
   Web of Science ®Google Scholar
• Rubin BP, Chen CJ, Morgan TW, et al. Congenital mesoblastic nephroma t(12;15) is associated with ETV6-NTRK3 gene fusion: cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma. Am J Pathol. 1998;153:1451–1458.
   PubMed Web of Science ®Google Scholar
• Vanden Borre P, Schrock AB, Anderson PM, et al. Pediatric, adolescent, and young adult thyroid carcinoma harbors frequent and diverse targetable genomic alterations, including kinase fusions. Oncologist. 2017;22:255–263.
   PubMed Web of Science ®Google Scholar
• Prasad ML, Vyas M, Horne MJ, et al. NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States. Cancer. 2016;122:1097–1107.
   PubMed Web of Science ®Google Scholar
• Ricarte-Filho JC, Li S, Garcia-Rendueles ME, et al. Identification of kinase fusion oncogenes in post-Chernobyl radiation-induced thyroid cancers. J Clin Invest. 2013;123:4935–4944.
   PubMed Web of Science ®Google Scholar
• Wu G, Diaz AK, Paugh BS, et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat Genet. 2014;46:444–450.
   PubMed Web of Science ®Google Scholar
• Stransky N, Cerami E, Schalm S, et al. The landscape of kinase fusions in cancer. Nat Commun. 2014;5:4846.
   PubMed Web of Science ®Google Scholar
• Versteeg R: R2: microarray analysis and visualization platform
   Google Scholar
• Jones DT, Hutter B, Jager N, et al. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet. 2013;45:927–932.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Li GG, Kim ST, et al. NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line. Oncotarget. 2015;6:39028–39035.
   PubMedGoogle Scholar
• Roberts KG, Li Y, Payne-Turner D, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014;371:1005–1015.
   PubMed Web of Science ®Google Scholar
• Sigal D, Tartar M, Xavier M, et al. Activity of entrectinib in a patient with the first reported NTRK fusion in neuroendocrine cancer. J Natl Compr Canc Netw. 2017;15:1317–1322.
   PubMed Web of Science ®Google Scholar
• Marchetti A, Felicioni L, Pelosi G, et al. Frequent mutations in the neurotrophic tyrosine receptor kinase gene family in large cell neuroendocrine carcinoma of the lung. Hum Mutat. 2008;29:609–616.
   PubMed Web of Science ®Google Scholar
• Doebele RC, Davis LE, Vaishnavi A, et al. An oncogenic NTRK fusion in a patient with soft-tissue sarcoma with response to the tropomyosin-related kinase inhibitor LOXO-101. Cancer Discov. 2015;5:1049–1057.
   PubMed Web of Science ®Google Scholar
• Kim S, Thiessen PA, Bolton EE, et al. PubChem substance and compound databases. Nucleic Acids Res. 2016;44:D1202–13.
   PubMed Web of Science ®Google Scholar
• Information NCfB: compound summary for CID 67330085. [cited 2018 Oct 4]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/67330085
   Google Scholar
• Hong D, Dowlati A, Burris I HA, et al. Clinical safety and activity from a Phase 1 study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions. Singapore: ESMO Asia; 2016.
   Google Scholar
• Moreno L. An active drug for TRK-positive paediatric solid tumours. Lancet Oncol. 2018;19:594-595.
   PubMed Web of Science ®Google Scholar
• Shukla N, Roberts SS, Baki MO, et al. Successful targeted therapy of refractory pediatric ETV6-NTRK3 fusion-positive secretory breast carcinoma. JCOPrecision Oncology. 2017.
   Google Scholar
• Turpin B, Albert CM, Mascarenhas L, et al. A pediatric phase 1 study of larotrectinib, a highly selective inhibitor of the tropomyosin receptor kinase (TRK) family: an updated analysis. Atlanta: AACR pediatric cancer research: from basic science to the clinic; 2017.
   Google Scholar
• Drilon A, Nagasubramanian R, Blake JF, et al. A next-generation TRK kinase inhibitor overcomes acquired resistance to prior TRK kinase inhibition in patients with TRK fusion-positive solid tumors. Cancer Discov. 2017;7:963–972.
   PubMed Web of Science ®Google Scholar
• Diaz LA, Marabelle A, Delord J-P, et al. Pembrolizumab therapy for microsatellite instability high (MSI-H) colorectal cancer (CRC) and non-CRC. J Clin Oncol. 2017;35:3071.
   Web of Science ®Google Scholar
• Shaw AT. Engelman JA: ALK in lung cancer: past, present, and future. J Clin Oncol. 2013;31:1105–1111.
   PubMed Web of Science ®Google Scholar
• Mosse YP, Voss SD, Lim MS, et al. Targeting ALK With crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor: a children’s oncology group study. J Clin Oncol. 2017;35:3215–3221.
   PubMed Web of Science ®Google Scholar
• Korphaisarn K, Kopetz S. BRAF-directed therapy in metastatic colorectal cancer. Cancer J. 2016;22:175–178.
   PubMed Web of Science ®Google Scholar
• Nagasubramanian R, Wei J, Gordon P, et al. Infantile fibrosarcoma with NTRK3-ETV6 fusion successfully treated with the tropomyosin-related kinase inhibitor LOXO-101. Pediatr Blood Cancer. 2016;63:1468–1470.
   PubMed Web of Science ®Google Scholar
• Schultz KR, Carroll A, Heerema NA, et al. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: children’s oncology group study AALL0031. Leukemia. 2014;28:1467–1471.
   PubMed Web of Science ®Google Scholar
• Saussele S, Richter J, Hochhaus A, et al. The concept of treatment-free remission in chronic myeloid leukemia. Leukemia. 2016;30:1638–1647.
   PubMed Web of Science ®Google Scholar
• Network NCC: NCCN clinical practice guidelines in oncology non-small cell lung cancer, Version 4. [cited 2018 May 9]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf, 2018
   Google Scholar